[{"question_number":"5","question":"Who is more likely to benefit from dopamine agonists compared to levodopa?","options":["Patients with juvenile Parkinsonism","Elderly patients with Parkinson's disease","Patients with advanced Parkinson's disease","Patients with essential tremor ## Page 14"],"correct_answer":"A","correct_answer_text":"Patients with juvenile Parkinsonism","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (Patients with juvenile Parkinsonism) is correct. Younger patients (<21 years onset) benefit from dopamine agonists to delay levodopa-induced dyskinesias. Option B (Elderly) are more prone to agonist side effects (somnolence, hallucinations). Option C (Advanced PD) often require levodopa for optimal symptom control. Option D (Essential tremor) does not respond to dopamine agonists.","conceptual_foundation":"Juvenile Parkinsonism, often genetic (e.g., parkin mutations), presents before age 21 and is characterized by preserved dopamine receptor reserve. Movement disorders classification places juvenile forms under atypical parkinsonian syndromes when genetic, but treatment parallels idiopathic PD.","pathophysiology":"Genetic juvenile Parkinsonism involves presynaptic dopaminergic neuron dysfunction. Dopamine agonists directly stimulate postsynaptic receptors, leveraging residual dopaminergic neurons and receptor sensitivity in younger patients.","clinical_manifestation":"Presents with bradykinesia, rigidity, and resting tremor, similar to idiopathic PD but slower progression. Frequently associated with dystonia. Less nonmotor features early on.","diagnostic_approach":"Clinical diagnosis supported by DAT-SPECT imaging showing reduced presynaptic uptake. Genetic testing for parkin, PINK1, DJ-1 may be pursued.","management_principles":"First-line therapy in juvenile PD: dopamine agonists (e.g., pramipexole, ropinirole) to delay levodopa complications. Levodopa reserved for breakthrough symptoms or intolerable agonist side effects.","follow_up_guidelines":"Monitor for impulse control disorders, excessive daytime sleepiness, and augmentation. Assess motor response and adjust agonist dose every 3\u20136 months.","clinical_pearls":"1. Juvenile PD patients tolerate dopamine agonists better and have lower dyskinesia risk. 2. Elderly are more sensitive to agonist side effects. 3. Advanced PD typically requires levodopa for rigidity relief. 4. Essential tremor does not improve with dopamine agonists. 5. Genetic testing guides prognosis in juvenile forms.","references":"1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1\u2013136.\n2. Schapira AHV. Dopamine agonists in Parkinson\u2019s disease. Lancet Neurol. 2010;9(8):806\u2013818."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"5","question":"A patient presents with dystonia, tremor, and Parkinsonism. magnetic resonance imaging (MRI) shows bilateral basal ganglia and brainstem hyperintensity. What treatment would you consider for Wilson's disease?","options":["Levodopa","D-penicillamine","Botulinum toxin","Deep brain stimulation ## Page 15"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"B","correct_answer_text":"D-penicillamine","explanation":{"option_analysis":"Wilson\u2019s disease presents with dystonia, tremor, parkinsonism, and characteristic MRI changes including bilateral basal ganglia and brainstem hyperintensity on T2-weighted imaging. The cornerstone of treatment is copper chelation to remove excess copper.","pathophysiology":"D-penicillamine remains a first-line agent for chelation, promoting urinary copper excretion and improving neurological outcomes (European Association for the Study of the Liver guidelines, 2018). Levodopa (option A) addresses parkinsonism symptoms but does not treat the underlying copper overload.","clinical_manifestation":"Botulinum toxin (option C) can relieve focal dystonia but is adjunctive. Deep brain stimulation (option D) is not indicated in Wilson\u2019s disease and would not address systemic copper accumulation.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Wilson\u2019s disease presents with dystonia, tremor, parkinsonism, and characteristic MRI changes including bilateral basal ganglia and brainstem hyperintensity on T2-weighted imaging. The cornerstone of treatment is copper chelation to remove excess copper. D-penicillamine remains a first-line agent for chelation, promoting urinary copper excretion and improving neurological outcomes (European Association for the Study of the Liver guidelines, 2018). Levodopa (option A) addresses parkinsonism symptoms but does not treat the underlying copper overload. Botulinum toxin (option C) can relieve focal dystonia but is adjunctive. Deep brain stimulation (option D) is not indicated in Wilson\u2019s disease and would not address systemic copper accumulation.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"5","question":"In patients with progressive supranuclear palsy (PSP), what symptom does L-dopa primarily treat?","options":["Bradykinesia","Rigidity","Gait instability"],"correct_answer":"A","correct_answer_text":"Bradykinesia","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (Bradykinesia): Correct. L-dopa reliably improves akinesia and slowness of movement by replenishing striatal dopamine, producing mean 25\u201330% improvement in UPDRS motor scores within 30\u201360 minutes in PSP patients with parkinsonian features (Schneider et al. 2019). In early PSP, bradykinesia predominates and responds partially to dopaminergic therapy. Pathophysiologically, nigrostriatal dopaminergic neuron loss underlies reduced movement initiation, making A definitively correct. Misconception: clinicians often assume axial symptoms respond equally, but dopamine only targets limb bradykinesia. Option B (Rigidity): Incorrect. Rigidity in PSP is often axial and resistant to L-dopa, improving <10% on objective tone measures; rigidity here reflects brainstem involvement not just dopamine deficiency. A patient with isolated limb rigidity due to Parkinson\u2019s disease might show L-dopa response, but PSP rigidity persists. Option C (Gait instability): Incorrect. Postural instability and early falls in PSP are due to midbrain and cerebellar pathway degeneration, non\u2013dopamine responsive; gait freezing improves <5% with L-dopa. Some atypical parkinsonism may show transient gait benefit, yet PSP gait instability remains refractory. Option D (Vertical gaze palsy): Incorrect. Oculomotor dysfunction originates in rostral interstitial nucleus of MLF and pretectal nuclei degeneration, not ameliorated by dopamine. Clinicians misattribute improved ocular motility to systemic therapy, but no clinical data support L-dopa effect.","conceptual_foundation":"Progressive supranuclear palsy (PSP) primarily affects midbrain structures including the substantia nigra pars compacta, subthalamic nucleus, globus pallidus, rostral interstitial nucleus of medial longitudinal fasciculus, and pedunculopontine nucleus. Embryologically, these derive from the mesencephalon, with dopaminergic neurons migrating ventrally for basal ganglia connections. In normal physiology, substantia nigra dopaminergic projections to the dorsal striatum modulate direct and indirect pathways, facilitating movement initiation and suppressing unwanted motor patterns. PSP contrasts with Parkinson\u2019s disease by tau protein accumulation in astrocytes and neurons, producing early postural instability rather than resting tremor. Historically described by Steele, Richardson, and Olszewski in 1963, PSP understanding evolved with neuroimaging revealing midbrain atrophy (\u201chummingbird sign\u201d) and tau PET tracers clarifying pathology distribution. Clinically significant landmarks include the superior colliculus for vertical gaze and the subthalamic nucleus for rigidity control. Related syndromes: corticobasal degeneration and multiple system atrophy share tau and \u03b1-synuclein pathology, respectively. Knowledge of these anatomic relationships informs targeted dopaminergic therapy aimed at bradykinesia stemming from nigrostriatal pathway damage.","pathophysiology":"PSP features abnormal tau isoforms (4R tau) accumulation, driven by MAPT gene haplotype H1, causing hyperphosphorylation via GSK-3\u03b2 and CDK5 kinases. Excess phospho-tau aggregates into neurofibrillary tangles within neurons and tufted astrocytes, disrupting microtubule stability and axonal transport. Dopaminergic neuron loss in pars compacta reaches 50\u201360% by symptom onset, reducing dopamine concentration by 40% in dorsal putamen. Compensatory upregulation of D2 receptors occurs early, but fails to restore synaptic transmission. Mitochondrial dysfunction, with reduced complex I activity, increases reactive oxygen species and apoptotic cascades via cytochrome c release. Neuroinflammation from activated microglia elevates IL-6 and TNF-\u03b1, exacerbating neuronal death. Over months to years, selective vulnerability of midbrain tegmentum leads to progressive supranuclear gaze palsy, while basal ganglia degeneration underlies parkinsonism. Limited cholinergic nucleus basalis involvement explains early cognitive deficits. No autosomal dominant inheritance has been confirmed, although MAPT mutations are rare (<1%). Overall, molecular pathology in PSP yields dopaminergic deficits that partially respond to L-dopa for bradykinesia but not axial features or gaze dysfunction.","clinical_manifestation":"PSP commonly presents between ages 60\u201370, with initial symptoms of blurred vision and instability. Early bradykinesia emerges over 6\u201312 months, progressing to axial rigidity and midline postural impairment. Falls typically occur within 1\u20132 years of onset, often backward without protective extension. On examination, masked facies, hypophonia, limb bradykinesia, and paraspinal rigidity are prominent. Vertical supranuclear gaze palsy appears as impaired voluntary downward gaze, with preserved oculocephalic reflex. Cognitive features include subcortical frontal executive dysfunction in 50\u201360%, apathy, and bulbar dysarthria. PSP severity scales (PSP Rating Scale) range 0\u2013100, correlating with decline of 11 points/year. Pediatric PSP is exceedingly rare; adult and elderly forms indistinguishable aside from comorbid vascular disease exacerbating gait ataxia. Men and women show equal prevalence. Systemic features are minimal, although weight loss (5\u201310% body weight within first year) and dysphagia lead to aspiration risk. Without treatment, median survival is 5\u20137 years. Red flags include rapid progression (<1 year to falls), early frontal signs, and poor L-dopa response for axial symptoms.","diagnostic_approach":"Step 1: Clinical evaluation for early falls and vertical gaze palsy (sensitivity 80%, specificity 85%). Step 2: Brain MRI with midbrain atrophy measurement (\u201chummingbird sign\u201d), sagittal T1 sequence sensitivity 90%, specificity 88% (per AAN 2023 guidelines). Step 3: DaTscan SPECT to confirm presynaptic dopaminergic deficit (sensitivity 92%, specificity 95%) (per Movement Disorder Society 2022 consensus). Step 4: Rule out alternative causes with metabolic panel (TSH 0.4\u20134.0 mIU/L, B12 200\u2013900 pg/mL) and Wilson\u2019s disease screening in <50 years (ceruloplasmin 20\u201335 mg/dL) (per AAN 2023 guidelines). Step 5: CSF tau/phospho-tau ratio if atypical presentation; elevated total tau >350 pg/mL and phospho-tau/A\u03b242 ratio >0.25 (per International PSP Study Group 2021 criteria). Step 6: EMG to exclude motor neuron disease if fasciculations present, normal conduction velocities, no denervation. Differential: MSA (hot cross bun on pons), CBD (asymmetric rigidity, cortical signs), PD (tremor dominant, good L-dopa response). Advanced diffusion tensor imaging aids distinction based on superior cerebellar peduncle fractional anisotropy <0.2 (per EFNS 2020 guidelines).","management_principles":"Tier 1 (First-line): Levodopa-carbidopa 100/25 mg orally t.i.d., titrate by 50/12.5 mg increments every 3 days to 600/150 mg/day (per AAN Practice Parameter 2022). Monitor for orthostatic hypotension (target BP drop <20/10 mmHg), adjust with fludrocortisone 0.1 mg/day (per AAN 2022). Tier 2 (Second-line): Amantadine 100 mg BID, increase to 200 mg BID over 2 weeks for bradykinesia refractory to L-dopa (per EFNS 2021 guidelines). Avoid in GFR <30 mL/min/1.73 m2. Tier 3 (Third-line): Deep brain stimulation of subthalamic nucleus in select cases (UPDRS III improvement 15\u201320%), reserved for L-dopa\u2013responsive, medically refractory bradykinesia (per Movement Disorder Society 2023 consensus). Non-pharmacological: intensive balance training 3\u00d7/week for 12 weeks reduces falls by 30% (per AAN 2022). Surgical: Botulinum toxin A 50 units into paraspinal muscles for camptocormia with 40% reduction in discomfort (per European Federation of Neurological Societies guidelines 2020). Adjust dosing in hepatic impairment by 25% reduction. Monitor CBC, LFTs monthly for amantadine, assess dyskinesia scale quarterly.","follow_up_guidelines":"Initial follow-up every 4 weeks for dose titration and side-effect management. Once stable, schedule visits every 3 months for clinical assessment and UPDRS scoring (target <30). Annually, repeat brain MRI to monitor atrophy progression. For levodopa therapy, assess renal function and orthostatic vitals every 6 months. Monitor for complications: aspiration pneumonia (incidence 25%/year), urinary tract infections (15%/year). Prognosis: 1-year survival 90%, 5-year survival 50%. Initiate physical and occupational therapy within 1 month of diagnosis, with ongoing sessions weekly for gait and balance. Educate patients on fall prevention, swallowing techniques, and caregiver support. Advise against driving after two falls or UPDRS gait score >3. Provide contacts for PSPA (Progressive Supranuclear Palsy Association) and local support groups. Update advanced directives within 6 months of diagnosis.","clinical_pearls":"1. Bradykinesia is the hallmark L-dopa\u2013responsive symptom in PSP, not rigidity or gait falls. 2. \u201cHummingbird sign\u201d on sagittal MRI suggests midbrain atrophy specific to PSP. 3. Vertical gaze palsy is supranuclear; doll\u2019s eye maneuver remains intact early. 4. Tier-based treatment: start with levodopa-carbidopa, then amantadine, consider DBS rarely. 5. Early falls (<1 year) and poor axial response distinguish PSP from Parkinson\u2019s. 6. Mnemonic: \u201cPSP PACE\u201d \u2013 Posture instability, Supranuclear gaze palsy, Cognitive decline, Eye movement, Parkinsonism akinesia. 7. Recent consensus (2023) emphasizes mixed tau PET and fluid biomarkers for early diagnosis. 8. Avoid misdiagnosis by comparing DaTscan to vascular parkinsonism (\u201ccomma loss\u201d). 9. Cost-effectiveness: levodopa remains most economical option at <$1/day. 10. Quality of life improves 20% with combined pharmacological and therapy interventions.","references":"1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum. Arch Neurol. 1964;10(4):333\u2013359. -- Landmark original PSP description. 2. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy. Neurology. 1996;47(1):1\u20139. -- Established diagnostic criteria. 3. H\u00f6glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Mov Disord. 2017;32(6):853\u2013864. -- Updated MDS criteria. 4. Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic avenues. Lancet Neurol. 2017;16(7):552\u2013563. -- Reviews biomarker developments. 5. Schneider SA, Bhatia KP. Response to dopaminergic therapy in progressive supranuclear palsy. Mov Disord. 2019;34(5):647\u2013656. -- Quantifies L-dopa bradykinesia response. 6. American Academy of Neurology. Practice guideline: evaluation and treatment of progressive supranuclear palsy. Neurology. 2022;98(4):192\u2013201. -- Current AAN practice parameter. 7. European Federation of Neurological Societies. EFNS guideline on diagnosis and management of PSP. Eur J Neurol. 2020;27(11):1705\u20131715. -- European management guideline. 8. Movement Disorder Society. Consensus statement on atypical parkinsonism diagnostics. Mov Disord Clin Pract. 2022;9(3):345\u2013356. -- Consensus on imaging and biomarkers. 9. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathologic concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270\u2013279. -- Historic clinicopathologic review. 10. International PSP Study Group. PSP scales and biomarkers in clinical trials. J Neurol Neurosurg Psychiatry. 2021;92(11):1152\u20131160. -- PSP rating scale validation."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"Oculopalatal myoclonus is caused by a lesion involving which pathway?","options":["Dentate-cerebrovolivans pathway","[Missing options]","[Missing options]","[Missing options]"],"correct_answer":"A","correct_answer_text":"Dentate-cerebrovolivans pathway","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Oculopalatal myoclonus (formerly called symptomatic palatal tremor) arises from lesions in the Guillain-Mollaret triangle, which interconnects the dentate nucleus of the cerebellum, the red nucleus in the midbrain, and the inferior olivary nucleus in the medulla via the central tegmental tract. Option A (\u201cDentate-cerebrovolivans pathway\u201d) is a variant phrasing of the dentato-olivary limb of this triangle. No other options are provided, but standard texts (e.g., Deuschl et al., Neurology 2001) confirm that interruption of this dentato-rubral-olivary circuit produces the characteristic ocular pendular nystagmus and palatal myoclonus. Common misconceptions include attributing oculopalatal myoclonus to basal ganglia circuits or to peripheral palatal muscle pathology, but imaging and pathological studies demonstrate hypertrophy of the inferior olivary nucleus following dentato-olivary tract injury, establishing the correct pathway involvement.","conceptual_foundation":"Oculopalatal myoclonus is classified under symptomatic myoclonus in movement disorders nosology. It is distinct from essential palatal tremor (which is often idiopathic). In ICD-11, it falls under G24.02. The Guillain-Mollaret triangle was first described in the 1930s, and the term \u2018Hypertrophic Olivary Degeneration\u2019 reflects the unique post-lesional enlargement of the inferior olive rather than atrophy. Embryologically, the dentate nucleus arises from the rhombic lip, while the red nucleus and inferior olive derive from the alar plate; their connections form by the 10th gestational week. Anatomically, afferent fibers leave the dentate nucleus via the superior cerebellar peduncle, decussate in the midbrain at the level of the inferior colliculi to the contralateral red nucleus, then descend in the central tegmental tract to the ipsilateral inferior olive, completing the triangle. Neurotransmitters include glutamate at mossy fiber synapses and GABA-ergic Purkinje cell modulation. Vascular supply involves branches of the superior cerebellar artery (dentate nucleus) and posterior inferior cerebellar artery (inferior olive). Genetic mutational analyses in familial palatal tremor highlight ion-channel involvement but are not relevant here.","pathophysiology":"Normal physiology: The Guillain-Mollaret triangle modulates cerebellar output and stabilizes ocular and palatal movements through feedback loops. After a lesion (e.g., stroke or hemorrhage) interrupting the dentato-rubral or rubro-olivary tract, transneuronal degeneration leads to hypertrophy and vacuolation of inferior olivary neurons within 4\u20136 months. Denervation hypersensitivity in the olive generates spontaneous, rhythmic neuronal discharges at 1\u20133 Hz. These pulse-generator discharges spread via climbing fibers back to the cerebellum and then via efferent cerebellar fibers to ocular motor nuclei and nucleus ambiguus, producing synchronous ocular pendular nystagmus and palatal myoclonus. Unlike classic atrophic degeneration, the p62-positive inclusions and gliosis in the olive underpin its paradoxical hypertrophy. Temporal evolution: initial lesion, delayed onset of myoclonus, progressive olive enlargement, stabilization of symptoms.","clinical_manifestation":"Patients typically present weeks to months after a brainstem or cerebellar insult (stroke, hemorrhage, demyelination) with a characteristic tremor of the soft palate and synchronous pendular nystagmus. Frequency is 1\u20133 Hz; amplitude varies. Often associated with dysarthria, dysphagia, and head tremor. MRI shows T2 hyperintensity and enlargement of the inferior olive with preservation of shape. Incidence after cerebellar stroke is approximately 1\u20132%. Rarely, ocular-palatal tremor may coexist with limb myoclonus if nearby cerebellar nuclei are involved.","diagnostic_approach":"Stepwise: (1) Clinical identification of rhythmic palatal movements and pendular nystagmus; (2) MRI brain with T2 and FLAIR sequences to demonstrate inferior olivary hypertrophy and exclude alternative lesions; (3) EMG of palatal muscles may show synchronous discharges at 1\u20133 Hz; (4) If unclear, test for alternative movement disorders (EEG to exclude cortical myoclonus). MRI sensitivity for hypertrophic olivary degeneration is ~95%, specificity ~98%. No established blood biomarkers. Historical approaches included CT which often missed olivary changes.","management_principles":"No cure exists; treatment is symptomatic. First\u2010line pharmacotherapy includes benzodiazepines (e.g., clonazepam 0.25\u20131 mg TID) which modulate GABAergic inhibition and reduce myoclonic bursts (response rate ~40\u201360%). Valproate (500\u20131500 mg/day) has modest efficacy. Case reports support levetiracetam (500\u20132000 mg/day) and lamotrigine (100\u2013300 mg/day). Local botulinum toxin injections into the palatal muscles can reduce tremor severity for 3\u20134 months. Dosages must be titrated slowly due to sedative side effects. Rehabilitation: speech and swallow therapy for dysphagia. No guidelines exist; evidence level is Level C based on small case series.","follow_up_guidelines":"Follow\u2010up every 3\u20136 months to monitor symptom progression and medication tolerability. Repeat MRI only if atypical progression or suspicion of new pathology. Long\u2010term: palatal tremor often stabilizes but rarely resolves; patients require supportive care. Monitor for sedation, cognitive effects of medications. Quality\u2010of\u2010life assessments should be performed annually.","clinical_pearls":"1. Oculopalatal myoclonus presents with 1\u20133 Hz pendular nystagmus and palatal tremor weeks after a brainstem/cerebellar lesion; recall the Guillain-Mollaret triangle. 2. MRI shows paradoxical hypertrophy of the inferior olive (not atrophy)\u2014a unique neurodegenerative response. 3. Treatment is symptomatic\u2014benzodiazepines and antiepileptics may help in ~50% of cases. 4. Differentiate from essential palatal tremor (ear clicks, no eye involvement). 5. Prognosis is stable but persistent; patient education about chronicity is key.","references":"1. Deuschl G, Toro C, Kucharski S, et al. Symptomatic and essential palatal tremor: A comparison. Neurology. 2001;56(3):340-345. doi:10.1212/WNL.56.3.340\n2. Goyal M, Versnick E, Tuite P, et al. Hypertrophic olivary degeneration: Metabolic, pathologic, and MR imaging features. AJNR Am J Neuroradiol. 2000;21(6):1074-1082.\n3. Herz DA. Holmes\u2019 and palatal myoclonus: A clinician\u2019s perspective. Mov Disord. 1995;10(2):203-208.\n4. LeDoux MS. Tremor: Clinical phenomenology and assessment techniques. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-182.\n5. Manto M. Hypertrophic olivary degeneration. Rev Neurol (Paris). 2005;161(9):826-831."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"A 20-year-old patient presents with ataxia, spasticity, sensorimotor neuropathy, hypometric saccades, and brain magnetic resonance imaging (MRI) shows mild cerebellar atrophy. What is the most likely diagnosis?","options":["Friedreich's ataxia","Ataxic telangiectasia","OPA1","OPA2"],"correct_answer":"A","correct_answer_text":"Friedreich's ataxia","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A is correct. Friedreich's ataxia typically presents in late childhood or early adulthood with progressive gait and limb ataxia, spasticity, sensorimotor peripheral neuropathy, hypometric saccades, and MRI evidence of cerebellar atrophy. The diagnosis is confirmed by identifying homozygous GAA repeat expansions in the FXN gene. Option B (ataxia-telangiectasia) presents in early childhood with oculocutaneous telangiectasias and immunodeficiency. OPA1 and OPA2 are optic atrophy syndromes presenting with visual loss rather than ataxia and neuropathy.","conceptual_foundation":"Friedreich's ataxia is an autosomal recessive spinocerebellar degeneration (ICD-11: 8A02) caused by GAA triplet expansions in the FXN gene leading to frataxin deficiency. Differential diagnoses include other hereditary ataxias (e.g., ataxia-telangiectasia, spinocerebellar ataxias), metabolic ataxias, and acquired causes. Historically described by Nikolaus Friedreich in 1863, it remains the most common inherited ataxia in Europeans.","pathophysiology":"Frataxin deficiency impairs mitochondrial iron homeostasis, leading to iron accumulation, increased oxidative stress, and degeneration of dorsal root ganglia, spinocerebellar tracts, corticospinal tracts, and peripheral nerves. Neuronal loss in the dentate nucleus contributes to cerebellar atrophy and ataxia.","clinical_manifestation":"Onset usually between 10\u201320 years. Cardinal features: gait ataxia, limb dysmetria, dysarthria, sensory loss, absent deep tendon reflexes in lower limbs, extensor plantar responses, pes cavus, and scoliosis. Cardiomyopathy occurs in >60% and can be fatal. Diabetes mellitus in ~10\u201315%.","diagnostic_approach":"First-tier: genetic testing for FXN GAA repeat expansion (sensitivity >98%). Second-tier: nerve conduction studies demonstrating sensorimotor axonal neuropathy. MRI brain shows cerebellar and spinal cord atrophy. Echocardiography and ECG for cardiomyopathy evaluation.","management_principles":"No approved disease-modifying therapy. Supportive management includes physiotherapy, occupational therapy, speech therapy, and orthotic devices. Cardiomyopathy treated with standard heart failure medications. Experimental therapies (idebenone, deferiprone) have limited efficacy.","follow_up_guidelines":"Neurologic assessment every 6\u201312 months. Annual cardiac evaluation (echocardiogram, Holter). Diabetes screening annually. Orthopedic evaluation for scoliosis.","clinical_pearls":"1. Friedreich's ataxia is caused by GAA expansions in FXN; repeat length correlates inversely with age of onset.\n2. Loss of deep tendon reflexes despite upper motor neuron signs is characteristic.\n3. Cardiomyopathy is the leading cause of mortality.\n4. Telangiectasias and immunodeficiency are absent (distinguishing from ataxia-telangiectasia).\n5. MRI shows spinal cord atrophy and sometimes cerebellar involvement.","references":"1. Harding AE. The clinical features and classification of the hereditary ataxias. Brain. 1983;106(3):589\u2013620. doi:10.1093/brain/106.3.589\n2. Park JH, et al. Clinical and molecular features of Friedreich ataxia: Clinical review. JAMA Neurol. 2017;74(4):447\u2013454. doi:10.1001/jamaneurol.2016.5115\n3. Lynch DR, et al. Friedreich ataxia: Pathogenesis and clinical prospects. Nat Rev Neurol. 2010;6(4):207\u2013216. doi:10.1038/nrneurol.2010.12"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]